Followers | 2543 |
Posts | 250732 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Thursday, July 20, 2023 2:04:21 PM
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.
“Reliefband is a leading innovator in wearable technology for the treatment of nausea and vomiting,” commented Rich Ransom, Chief Executive Officer of Reliefband Technologies. “Partnering with electroCore to distribute our prescription non-invasive, non-drug, neuromodulation device seemed like a natural fit. We are excited about the collaboration and hopeful the relationship will provide our veterans access to another FDA cleared non-drug solution.”
“We are thrilled to be offering the Reletex product within VA hospitals and other FSS eligible entities,” commented Dan Goldberger, Chief Executive Officer of electroCore. “We continue to build out our commercial sales organization and look for unique and complementary therapies which can be made available to our customer base. The drug-free, patient-controlled Reletex product is ideal for veterans suffering from nausea and vomiting and we believe it will be well adopted by customers who utilize neuromodulation devices such as our existing gammaCore™ therapy to treat medical conditions.”
About Reliefband Technologies, LLC
Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com.
About ReletexTM
Reletex is an advanced pulse generator that utilizes neuromodulation technology. It is the First-Class II neuromodulation device cleared by the FDA for the therapy of nausea and vomiting. Reletex is a single patient use device and can function with its included set of non-replaceable/non-rechargeable batteries for approximately 150 hours when used on setting 3. Reletex is available by prescription for the treatment of nausea and vomiting as an adjunct to antiemetics.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects through distribution of Reletex within the Department of Veterans Affairs or other FSS eligible entities or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
Recent ECOR News
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:04:51 PM
- Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- electroCore Announces the Launch of Truvaga Plus® for General Wellness • GlobeNewswire Inc. • 04/08/2024 12:30:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- electroCore Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- electroCore to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 • GlobeNewswire Inc. • 03/05/2024 09:05:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:00:51 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:16:30 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 12/26/2023 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 09:15:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 12/18/2023 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:15:26 PM
- electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/07/2023 12:53:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 11:11:39 AM
- Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023 • GlobeNewswire Inc. • 11/15/2023 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:16:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:11:31 PM
- electroCore Announces Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 09:01:00 PM
- electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM